Beigene Ltd (NASDAQ:BGNE) has earned a consensus rating of “Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $178.29.

A number of analysts have commented on BGNE shares. Maxim Group set a $170.00 target price on Beigene and gave the stock a “buy” rating in a report on Friday, August 9th. Macquarie started coverage on Beigene in a report on Friday, July 5th. They issued an “underperform” rating for the company. Zacks Investment Research raised Beigene from a “hold” rating to a “strong-buy” rating and set a $133.00 target price for the company in a report on Wednesday, October 9th. Piper Jaffray Companies reissued a “buy” rating on shares of Beigene in a report on Thursday, June 20th. Finally, Morgan Stanley reduced their target price on Beigene from $201.00 to $200.00 and set an “overweight” rating for the company in a report on Friday, October 11th.

In related news, CMO Jane Huang sold 2,500 shares of Beigene stock in a transaction on Monday, August 12th. The stock was sold at an average price of $134.74, for a total value of $336,850.00. Following the completion of the sale, the chief marketing officer now owns 328,873 shares of the company’s stock, valued at $44,312,348.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Timothy Yung-Cheng Chen sold 8,614 shares of Beigene stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $144.96, for a total value of $1,248,685.44. The disclosure for this sale can be found here. Insiders sold 24,106 shares of company stock valued at $3,361,842 in the last ninety days. 13.40% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Capital Investment Advisory Services LLC bought a new stake in shares of Beigene in the second quarter worth $26,000. Ladenburg Thalmann Financial Services Inc. grew its holdings in Beigene by 24.8% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 443 shares of the company’s stock valued at $55,000 after purchasing an additional 88 shares during the period. Riverhead Capital Management LLC grew its holdings in Beigene by 28.6% during the second quarter. Riverhead Capital Management LLC now owns 450 shares of the company’s stock valued at $56,000 after purchasing an additional 100 shares during the period. Tower Research Capital LLC TRC grew its holdings in Beigene by 1,500.0% during the second quarter. Tower Research Capital LLC TRC now owns 592 shares of the company’s stock valued at $73,000 after purchasing an additional 555 shares during the period. Finally, Marshall Wace North America L.P. bought a new stake in Beigene during the first quarter valued at about $76,000.

Beigene stock opened at $124.82 on Friday. The firm has a market cap of $5.67 billion, a price-to-earnings ratio of -10.27 and a beta of 0.99. The stock has a fifty day simple moving average of $129.09 and a two-hundred day simple moving average of $129.07. Beigene has a 12 month low of $105.19 and a 12 month high of $164.99. The company has a current ratio of 6.46, a quick ratio of 6.28 and a debt-to-equity ratio of 0.15.

Beigene (NASDAQ:BGNE) last posted its earnings results on Thursday, August 8th. The company reported ($1.43) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.01) by $1.58. The business had revenue of $243.35 million during the quarter, compared to analyst estimates of $65.58 million. Beigene had a negative return on equity of 38.41% and a negative net margin of 153.32%. The company’s quarterly revenue was up 360.8% compared to the same quarter last year. During the same quarter last year, the company earned ($2.92) EPS. On average, equities research analysts forecast that Beigene will post -10.98 EPS for the current fiscal year.

About Beigene

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Read More: What is the Dividend Aristocrat Index?

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.